Abstract 80P
Background
HLX26 is a novel humanised anti-lymphocyte activation gene-3 monoclonal antibody. This study aimed to evaluate the safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab (a novel programmed cell death-1 inhibitor) in patients with advanced solid tumours.
Methods
This was a single-centre, open-label, dose-escalation phase 1 study. Patients with histologically or cytologically confirmed advanced/metastatic solid tumours that had failed or could not receive standard therapies were enrolled and received intravenous HLX26 at three dose levels (500, 800, 1600 mg) plus serplulimab (300 mg) Q3W, following a “3+3” design. The primary endpoint was dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) within three weeks after the first administration of HLX26 (i.e. the DLT observation period). Secondary endpoints included safety, preliminary efficacy, pharmacokinetics, and immunogenicity.
Results
As of 19 July 2023, 9 patients with primary stage IV non-small cell lung cancer (n=4, 44.4%), small cell lung cancer (n=2, 22.2%), gastric cancer (n=1, 11.1%), cervical cancer (n=1, 11.1%), or endometrial cancer (n=1, 11.1%) were enrolled and received HLX26 at 500 mg (n=3), 800 mg (n=3), or 1600 mg (n=3), in combination with 300 mg serplulimab. The median age was 66 years, and 6 (66.7%) patients were male. All patients experienced treatment-emergent adverse events (TEAEs); all TEAEs that occurred during the DLT observation period were grade 1 or 2. One patient in the 800 mg group reported grades 3 or 4 drug-related asthenia, pain, and neutrophil count decreased. No DLT was reported and the MTD was not determined yet. Among the 8 efficacy evaluable patients, none had achieved complete or partial response; 3 (37.5%) patients (one in each group) had a best overall response of stable disease.
Conclusions
No new safety signals were observed for the different doses of HLX26 in combination with serplulimab. HLX26 plus serplulimab was safe and well tolerated in patients with advanced solid tumours who had failed or could not receive standard therapies.
Clinical trial identification
NCT05400265 (released on 1 June 2022).
Editorial acknowledgement
Editorial assistance was provided by Zhi Hao Kwok, Shiqi Zhong, and Chen Hu of Shanghai Henlius Biotech, Inc.
Legal entity responsible for the study
Shanghai Henlius Biotech, Inc.
Funding
Shanghai Henlius Biotech, Inc.
Disclosure
H. Li, W. Kang, J. Li, Q. Wang, J. Zhu: Financial Interests, Personal, Full or part-time Employment: Shanghai Henlius Biotech, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract